The FDA approval makes Epkinly the first T cell-engaging bispecific antibody for the subcutaneous treatment of relapsed or refractory follicular lymphoma, according to the partners
Mistake 4: poor injection technique Contamination, incorrect injection depth, failure to rotate sites, and improper reconstitution all reduce effectiveness and increase risk
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
They accomplish this by binding to specific receptors on cell surfaces and activating biological pathways that stimulate tissue repair, reduce inflammation, and improve circulation to injured areas